GM Allotypes and COVID-19. A Pilot Study Performed on Sicilian Patients.

Transl Med UniSa

Laboratory of Immunopathology and Immunosenescence, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, Palermo, Italy.

Published: December 2022

Several studies suggest that genetic variants that influence the onset, maintenance and resolution of the immune response might be fundamental in predicting the evolution of COVID-19. In the present paper, we analysed the distribution of GM allotypes (the genetic markers of immunoglobulin γ chains) in symptomatic and asymptomatic COVID-19 patients and in healthy controls, all born and residing in Sicily. Indeed, the role played by GM allotypes in immune responses and infection control is well known. Our findings show that the GM23 allotype is significantly reduced in healthy controls. Interestingly, in a previous study, Sicilians carrying the GM23 allotype were associated with the risk of developing a symptomatic Human Cytomegalovirus infection. However, a note of caution should be considered, due to the small sample size of patients and controls.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354864PMC
http://dx.doi.org/10.37825/2239-9747.1039DOI Listing

Publication Analysis

Top Keywords

healthy controls
8
gm23 allotype
8
allotypes covid-19
4
covid-19 pilot
4
pilot study
4
study performed
4
performed sicilian
4
sicilian patients
4
patients studies
4
studies genetic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!